RECORD // Company

Biohaven Ltd.

Formerly: Biohaven Research Ltd.

Built 2026-11-22T00:10:48Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • BIOHAVEN · Epa echo · exact name match to 'Biohaven Ltd.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-10-29 · accession 0001935979-26-000092

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-129,279,0003 months ended 2026-09-3010-Q2026-10-290001935979-26-0000922026-11-22 00:10 UTCReport an error
Cash and cash equivalents$95,754,000at 2026-09-3010-Q2026-10-290001935979-26-0000922026-11-22 00:10 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001935979
Ticker
BHVN
CUSIP
G1110E107
Record ID
sx:sec:0001935979

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

28 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 00:10 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-22 00:10 UTCReport an error
State of incorporationD82026-11-16SEC EDGAR company profile2026-11-22 00:10 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 00:10 UTCReport an error
Business address215 CHURCH STREET, NEW HAVEN, CT, 065102026-11-16SEC EDGAR company profile2026-11-22 00:10 UTCReport an error
ExchangesNYSE2026-11-16SEC EDGAR company profile2026-11-22 00:10 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-738,822,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:10 UTCReport an error
Total assets (at 2025-12-31)$451,447,0002025-12-3110-K, XBRL Assets2026-11-22 00:10 UTCReport an error
Stockholders' equity (at 2025-12-31)$52,072,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:10 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$229,957,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:10 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-609,438,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:10 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$715,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 00:10 UTCReport an error
Operating lease liabilities (at 2025-12-31)$45,714,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 00:10 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-16)Biohaven Ltd. will be making an investor presentation (the “Presentation”) at the Jefferies Global Healthcare Conference in London, United Kingdom starting today (November 16-19). A copy of the Presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference. The information in this Item 7.01, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of…2026-11-16SEC EDGAR 8-K 0001935979-26-000096 (text as filed, excerpt)2026-11-22 00:10 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-10-29)On October 29, 2026, Biohaven Ltd. (the “Registrant”) issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act…2026-10-29SEC EDGAR 8-K 0001935979-26-000093 (text as filed, excerpt)2026-11-22 00:10 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-22)On October 22, 2026, Biohaven Ltd. (the Company) provided an update on the spinocerebeller ataxia (SCA) program. The FDA has informed Biohaven that the company’s new drug application resubmission for Vyglxia (troriluzole) in SCA has been accepted for review. The resubmission included new positive supportive analyses. The FDA communicated that it considers the resubmission a complete response to the November 4, 2025 action letter, and has assigned a user fee goal date in the first quarter of 2027. The FDA plans to convene a meeting of the Peripheral and Central Nervous System Advisory Committee to obtain input from external stakeholders. The anticipated date of the advisory committee meeting…2026-10-22SEC EDGAR 8-K 0001935979-26-000083 (text as filed, excerpt)2026-11-22 00:10 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-10-15)Collaboration and License Agreement On October 8, 2026, Biohaven Ltd., together with its wholly owned subsidiaries (the “Company”), entered into a Collaboration and License Agreement (the “License Agreement”) with Ono Pharmaceutical Co., Ltd. (“Ono”). Pursuant to the License Agreement, the Company granted Ono an exclusive, royalty-bearing license, with the right to grant sublicenses subject to the terms of the License Agreement, to develop and commercialize the Company’s MoDE™ pan IgG degrader portfolio, led by BHV-1300 and including next-generation follow-on degraders BHV-1310 and BHV-1320, in Japan, South Korea, Taiwan and the countries of the Association of Southeast Asian Nations (the…2026-10-15SEC EDGAR 8-K 0001935979-26-000080 (text as filed, excerpt)2026-11-22 00:10 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-15)On October 8, 2026, the Company issued a press release announcing the transaction contemplated by the License Agreement. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth…2026-10-15SEC EDGAR 8-K 0001935979-26-000080 (text as filed, excerpt)2026-11-22 00:10 UTCReport an error
Largest institutional holder #1 (13F as filed): BlackRock, Inc.$196,573,5052026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:10 UTCReport an error
Largest institutional holder #2 (13F as filed): MONTANOVA CAPITAL, LLC$153,069,6232026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:10 UTCReport an error
Largest institutional holder #3 (13F as filed): STIFEL FINANCIAL CORP$147,924,5302026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:10 UTCReport an error
Largest institutional holder #4 (13F as filed): Jupiter Topco LLC$127,851,5752026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:10 UTCReport an error
Largest institutional holder #5 (13F as filed): Woodline Partners LP$113,984,9662026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:10 UTCReport an error
Largest institutional holder #6 (13F as filed): STATE STREET CORP$103,371,8662026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:10 UTCReport an error
Largest institutional holder #7 (13F as filed): INFINITUM ASSET MANAGEMENT, LLC$93,000,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:10 UTCReport an error
Largest institutional holder #8 (13F as filed): D. E. Shaw & Co., Inc.$62,350,1022026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:10 UTCReport an error
Largest institutional holder #9 (13F as filed): AQR CAPITAL MANAGEMENT LLC$61,761,1592026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:10 UTCReport an error
Largest institutional holder #10 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$49,460,2732026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:10 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.